https://www.statnews.com/2021/10/21/athira-chief-executive-resigns-as-company-confirms-she-altered-research/ STAT * * * Contribute * Subscribe * Log In Try STAT+ Today My Account * My Account * Billing * Log Out Try STAT+ Today My Account [ ] Search Back * Topics + Coronavirus + Health + Pharma + Biotech + Politics & Policy + Health Tech + In the Lab + Business + Artificial Intelligence + Vaccines + Health Disparities + Prescription Politics * Opinion + First Opinion + The Pharmalot View + Adam's Take + Matt's Take + Off the Charts * Team + Biotech & Pharma o Adam Feuerstein o Damian Garde o Matthew Herper o Meghana Keshavan o Kate Sheridan o Ed Silverman + Health Tech o Mario Aguilar o Erin Brodwin o Katie Palmer o Casey Ross + Politics o Rachel Cohrs o Lev Facher o Nicholas Florko + Health & Science o Eric Boodman o Helen Branswell o Elizabeth Cooney o Isabella Cueto o Olivia Goldhill o Andrew Joseph o Usha Lee McFarling o Megan Molteni o Jennifer Adaeze Okwerekwu o Nicholas St. Fleur + Team o View All * Events + STAT Events + Industry Events Calendar + 2021 STAT Summit + View all Summits + Webinars * Newsletters * Reports * Video * Podcasts + The Readout LOUD + First Opinion Podcast * * STAT+ + STAT+ Exclusive analysis of biotech, pharma, and the life sciences Learn More o The Latest o My Account + Topics o Biotech o Pharma o Policy o Health Tech o Business + Columns o Adam's Take o Matt's Take o The Pharmalot View + Tools o CRISPR Tracker o Drug Pricing Policy Tracker + Events o STAT+ Conversations o All STAT Events + Team o Biotech and Pharma o Health Tech o Politics and Policy o Health and Science Account * My Account * Billing * Subscribe * Log In * Help More * Contribute * Group Subscriptions Follow Us * * * * * Trending: Coronavirus Pharmalot Biotech Health Biotech Athira chief executive resigns as company confirms she altered research * Olivia Goldhill By Olivia Goldhill Oct. 21, 2021 Reprints * * * * * * * * * Leen Kawas WSU Leen Kawas, the former CEO of Athira Pharmaceuticals. Washington State University photo services * * * * * * * * * The chief executive of biotech Athira Pharma has permanently left the company after papers she published as a graduate student were found to contain altered research. Leen Kawas was suspended in June, after STAT asked the Alzheimer's research company to comment on the allegations, and Athira announced her resignation as president, chief executive, and member of the board of directors today. Mark Litton, the company's chief operating officer, will take Kawas' place to lead Athira. Athira's board of directors' special committee investigation found that Kawas altered images in at least four research papers she co-authored while she was a graduate student at Washington State University. advertisement "The company and Dr. Kawas agreed it is in Athira's best interest to enter this critical next chapter under new leadership," said Kelly Romano, chair of Athira's board of directors, in a statement. "Dr. Kawas's actions at Washington State University took place many years ago and did not involve ATH-1017, Athira's lead development candidate," a potential treatment for Alzheimer's. The altered images in Kawas' papers, first reported by STAT, depict Western blots containing several bands that appear repeatedly. advertisement Though none of the papers were cited in the patent granted to Athira in June 2021 for its lead drug candidate, ATH-1017, the altered research has nevertheless played a role in Athira's development. Two of the papers were cited in a 2013 patent granted to the company, while three altered papers co-authored by Kawas were referenced in an Athira application for $15 million funding from the National Institutes of Health, which STAT obtained through a Freedom of Information request. Related: Athira cited altered studies in $15 million NIH grant application, creating legal risk Athira is currently subject to several class-action lawsuits on behalf of shareholders, alleging the company made false and misleading statements about its research to the Securities and Exchange Commission. The company remains confident in its lead drug candidate, said Litton, while Romano said Athira "remains absolutely committed to the integrity of scientific research." Kawas said she supported Athira's work going forward: "I remain confident in the Company's ability to realize its mission and bring the Company's lead development candidates to market." * * * * * * * * * About the Author Reprints Olivia Goldhill Olivia Goldhill Investigative Reporter Olivia is an investigative reporter at STAT, working to hold corporations and public bodies to account in their response to Covid-19. [email protected] @OliviaGoldhill Tags biotechnology dementia research Create a display name to comment This name will appear with your comment [ ] There was an error saving your display name. Please check and try again. [Continue] Trending melioidosis petri dish Deadly infection linked to contaminated room spray sold at... Deadly infection linked to contaminated room spray sold at Walmart moderna syringes FDA authorizes booster shots of Moderna, Johnson & Johnson... FDA authorizes booster shots of Moderna, Johnson & Johnson Covid-19 vaccines vaccine silhouette Comparing the Covid-19 vaccines developed by Pfizer, Moderna, and... Comparing the Covid-19 vaccines developed by Pfizer, Moderna, and Johnson & Johnson Recommended [] Listen: Inside the vaccine race, how a Covid pill... Listen: Inside the vaccine race, how a Covid pill failed, & Biogen's troubled launch dark bedroom What the death rattle and capital punishment have in... What the death rattle and capital punishment have in common Cambridge: Biogen Biogen's Aduhelm sales fall dramatically below Wall Street's expectations Biogen's Aduhelm sales fall dramatically below Wall Street's expectations More in Biotech Cambridge: Biogen Biotech Biogen's Aduhelm sales fall dramatically below Wall Street's expectations By Damian Garde and Adam Feuerstein red c19 micrograph Biotech Atea's antiviral pill fails to clear Covid-19, forcing a re-think By Damian Garde and Matthew Herper advertisement [330x400-00] Health Tech A disrupting force, or 'just another mail order pharmacy'? How Amazon Pharmacy stacks up a year after launching By Erin Brodwin Gillis Ad A STAT Investigation Selling certainty: In a sea of skeptics, this physician was one of fibromyalgia patients' few true allies. Or was he? By Eric Boodman data thief Health Tech 'My jaw dropped': Basic security flaws in third-party apps leave millions of patient records at risk By Katie Palmer STAT Reporting from the frontiers of health and medicine Trending: * Coronavirus * Pharmalot * Biotech * Health * First Opinion * Pharma Back to top Company * About * Our Team * Contact Us * Work at STAT * Internships at STAT * Pitch STAT * STAT's Diversity and Inclusion Committee * Sharon Begley-STAT Science Reporting Fellowship * Awards * Contribute * Licensing Stories STAT+ * Learn More * FAQs * Subscribe * Log In * Billing * Help Group Subscriptions * Request A Quote * Contact Us Advertising * Download Media Kit * Advertise With Us Apps & Media * Newsletters * STAT App * Podcasts * STAT Reports * STAT Madness * STAT Wunderkinds Events * STAT Events * Industry Events Calendar * Sponsor Our Events * Privacy * Comment Policy * Terms * Do Not Sell my Data * (c)2021 STAT * * * * * * *